Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: pignata s. Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023. Front Oncol. 2023. PMID: 37781174 Free PMC article.
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G; Multicenter Italian Trials in Ovarian Cancer invesitgators. Lorusso D, et al. Among authors: pignata s. Ann Oncol. 2003 Jul;14(7):1086-93. doi: 10.1093/annonc/mdg301. Ann Oncol. 2003. PMID: 12853351 Free article. Clinical Trial.
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. Pignata S, et al. Br J Cancer. 2007 Jun 4;96(11):1639-43. doi: 10.1038/sj.bjc.6603787. Epub 2007 May 8. Br J Cancer. 2007. PMID: 17486128 Free PMC article. Clinical Trial.
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Lorusso D, et al. Among authors: pignata s. Ann Oncol. 2010 Jan;21(1):61-6. doi: 10.1093/annonc/mdp266. Epub 2009 Jul 15. Ann Oncol. 2010. PMID: 19605508 Free article. Clinical Trial.
471 results